Roffman Miller Associates Inc. PA Purchases New Position in Eli Lilly and Company $LLY

Roffman Miller Associates Inc. PA acquired a new stake in Eli Lilly and Company (NYSE:LLY) in the third quarter, according to its most recent filing with the SEC. The fund acquired 16,522 shares of the company’s stock, valued at approximately $12,606,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Lazard Freres Gestion S.A.S. raised its holdings in shares of Eli Lilly and Company by 114.3% during the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after buying an additional 41,222 shares in the last quarter. Precedent Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after acquiring an additional 39 shares in the last quarter. Central Pacific Bank Trust Division raised its stake in shares of Eli Lilly and Company by 25.8% during the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock worth $6,859,000 after acquiring an additional 1,843 shares in the last quarter. Capital Advisors Inc. OK grew its stake in shares of Eli Lilly and Company by 6.8% during the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after buying an additional 429 shares during the last quarter. Finally, Family CFO Inc bought a new position in shares of Eli Lilly and Company during the second quarter valued at about $54,000. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Daiwa America raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, December 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. BMO Capital Markets set a $1,200.00 price target on shares of Eli Lilly and Company in a report on Thursday, December 4th. JPMorgan Chase & Co. raised their target price on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 18th. Finally, CICC Research boosted their price target on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a research report on Thursday, November 13th. Four analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,155.36.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Zacks raised quarterly and full‑year EPS estimates for LLY, reflecting stronger-than-expected GLP-1 and franchise momentum which supports earnings upside. Zacks raises LLY estimates
• Positive Sentiment: Forbes outlines three possible catalysts that could trigger an LLY rally (pipeline readouts, successful oral GLP‑1 launch execution and M&A/partnerships), providing a roadmap for upside if Lilly executes. 3 Catalysts That Can Start An Eli Lilly Stock Rally
• Positive Sentiment: High‑profile bullish commentary (e.g., Jim Cramer) and positive Phase‑3/clinical data updates (breast cancer, EMBER‑3 imlunestrant results) keep long‑term conviction intact for growth beyond obesity drugs. Jim Cramer on Lilly
• Positive Sentiment: Broker support remains: Bank of America and others maintain Buy/overweight views and some firms have raised price targets based on eventual realization of obesity‑drug earnings. This provides analyst backing for potential rebounds. BofA maintains Buy on Eli Lilly
• Neutral Sentiment: Sector rotation into healthcare/XLV increases passive demand for LLY (it’s a large ETF holding), supporting structural investor interest even amid short‑term volatility. Sector Rotation: 2 Smart Money Moves for 2026
• Neutral Sentiment: Deal speculation (reported meetings with Abivax/French officials) and ongoing partnership chatter could be upside optionality but are early-stage and uncertain. Abivax soars on Lilly meeting report
• Negative Sentiment: Major near-term headwind: the FDA approved Novo Nordisk’s oral Wegovy pill — the first daily oral obesity drug — giving Novo a first‑mover advantage that could pressure Lilly’s orforglipron launch timing/market share and is driving the stock pullback. Novo Nordisk weight-loss drug wins US approval as a daily pill
• Negative Sentiment: Market reaction and commentary: multiple outlets report LLY shares falling as investors re‑price competitive risk and potential slower or lower peak sales for Lilly’s oral GLP‑1; near‑term investor focus will be on comparative efficacy, launch execution, and pricing dynamics. Eli Lilly Stock Falls. Novo Nordisk Got a Wegovy Weight-Loss Pill Approved in U.S.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $1,070.80 on Wednesday. The business has a fifty day moving average price of $971.08 and a 200-day moving average price of $835.68. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The company has a market capitalization of $1.01 trillion, a PE ratio of 52.39, a PEG ratio of 1.09 and a beta of 0.37. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. Eli Lilly and Company’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.